Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tunlametinib + gemcitabine + albumin-bound paclitaxel + cetuximab beta
- Development stage
- Unknown
- Lead developer
- Shanghai KeChow Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy is a four-drug regimen being evaluated as a first-line treatment for advanced pancreatic cancer. It consists of **tunlametinib** (HL-085), a potent and selective small-molecule inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2); **gemcitabine**, a nucleoside metabolic inhibitor; **albumin-bound paclitaxel**, a microtubule inhibitor; and **cetuximab β**, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR). The rationale for this combination is to simultaneously inhibit the MAPK pathway (via MEK inhibition) and the EGFR pathway while utilizing standard-of-care cytotoxic chemotherapy (gemcitabine/nab-paclitaxel) to overcome resistance and improve clinical outcomes in treatment-naive patients with advanced pancreatic adenocarcinoma. The study is led by the Tianjin Medical University Cancer Institute and Hospital.
- Brand names
- Abraxane
- Other names
- Tunlametinib + Gemcitabine + Albumin Paclitaxel + Cetuximab βTunlametinib + Chemotherapy + Cetuximab β
02
Targets
TUBB (Tubulin (alpha and beta subunits))RNR (Ribonucleotide reductase)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on tunlametinib + gemcitabine + albumin-bound paclitaxel + cetuximab beta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tunlametinib + gemcitabine + albumin-bound paclitaxel + cetuximab beta.